The discovery that glucagon-like peptide 1 (GLP-1) mediates a significant proportion of the
incretin effect during the postprandial period and the subsequent observation that GLP-1 …

Glucagon-like peptide-1 (GLP-1), an incretin hormone secreted primarily from the intestinal
L-cells in response to meals, modulates nutrient homeostasis via actions exerted in multiple …

Glucagon‐like peptide 1 (GLP‐1) is a gut‐derived incretin hormone with the potential to
change diabetes. The physiological effects of GLP‐1 are multiple, and many seem to …

Glucagon-like peptide (GLP)-1 is an incretin hormone with potent glucose-dependent
insulinotropic and glucagonostatic actions, trophic effects on the pancreatic β-cells, and …

Cardiovascular disease is a leading cause of death in the United States and across the
world, and better therapies are constantly being sought to improve patient outcomes. Recent …

Incretins, enhancers of insulin secretion, are essential for glucose tolerance, and a reduction
in their function might contribute to poor β-cell function in patients with type-2 diabetes …

In healthy individuals, the incretin hormone glucagon-like peptide 1 (GLP1) potentiates
insulin release and suppresses glucagon secretion in response to the ingestion of nutrients …

The gut-derived incretin hormone, glucagon-like peptide 1 (GLP-1) lowers postprandial
blood glucose levels by stimulating insulin and inhibiting glucagon secretion. Two novel …

Type 2 diabetes mellitus is a well‐established risk factor for cardiovascular disease (CVD).
New therapeutic approaches have been developed recently based on the incretin …

The incretin hormone, glucagon-like peptide-1 (GLP-1), is now being used in the clinic to
enhance insulin secretion and reduce body weight in patients with type 2 diabetes. Although …